Marco Timmers, Ph.D.

Marco Timmers is Chief Executive Officer at Byondis. He is an established leader with more than two decades of experience in pharmaceutical research and development and an extensive network spanning both industry and academia. Prior to his appointment as Byondis CEO, Timmers held the position of Chief Scientific Officer of Synthon Biopharmaceuticals (which later became Byondis) since it became a Synthon subsidiary in 2012. In this role, he was responsible for the development of a pipeline of new biological and chemical molecular entities, including monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs) and small molecules. Before joining Synthon Biopharmaceuticals, Timmers worked for more than 15 years at Organon, Schering-Plough and MSD. During this period, he held positions of increasing responsibility, ultimately serving as Head of Pharmacology and Site Lead for Women’s Health and Endocrinology and as a member of the R&D and Site Management teams. Timmers holds an MSc in Chemistry and a PhD in Bioorganic Chemistry, both from Leiden University, the Netherlands.